证券代码：688373 证券简称：盟科药业 公告编号：2026-004 上海盟科药业股份有限公司 专利申请日：2008年8月6日 专利权人：上海盟科药业股份有限公司 涉及药品：康替唑胺片 自愿披露关于公司核心产品专利 获得期限补偿的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，上海盟科药业股份有限公司（以下简称"公司"）收到国家知识产权局下发的《药品专利权期限补 偿审批决定》，现将相关情况公告如下： 一、涉及药品专利基本情况 专利号：ZL200880020610.0 专利名称：用于治疗细菌感染的抗菌邻-氟苯基噁唑烷酮 董事会 2026年1月9日 二、药品专利权期限补偿审批决定主要内容 按照中国专利法及其实施细则相关规定，决定给予该专利药品专利权期限补偿，补偿天数1826天，原专 利权期满终止日2028年8月6日，现专利权期满终止日2033年8月6日。药品专利权期限补偿期间，其保护 范围限于国务院药品监督管理部门批准上市的新药，且限于该新药经批准的适应症相关技术方案。 三、对公司的影响 康替唑胺片作为公司核心产 ...

《科创板日报》1月8日讯 今日科创板晚报主要内容包括：工信部牵头警示锂电池产业非理性竞争；广 州：聚焦攻关可重复使用火箭技术；沪硅产业：大基金1月7日至1月8日期间累计减持0.2%股份。 【热点聚焦】 简讯： 工信部牵头警示锂电池产业非理性竞争 十余家头部企业参与 工信部官微发文称，工信部、国家发展改革委、市场监管总局、国家能源局于1月7日联合召开动力和储 能电池行业座谈会(下称座谈会)，研究部署进一步规范动力和储能电池产业竞争秩序工作。据记者自知 情人士处获悉，本次会议召集了16家企业，包括13家动力电池与储能电池企业：宁德时代、比亚迪、中 创新航、国轩高科、亿纬锂能、欣旺达、蜂巢能源、瑞浦兰钧、鹏辉能源、海辰储能、正力新能、浙江 吉曜通行能源科技、楚能新能源。另有3家系统集成商：中车株洲所、海博思创、天合储能。此外，有 行业媒体报道称，中国汽车动力电池创新联盟、中国化学物理电源行业协会全程参与此次座谈会，对行 业自律进行倡导。 业内人士：市场监管总局约谈6家光伏龙头及行业协会 不得约定产能及销售价格等 日前有市场传闻称，市场监管总局约谈了中国光伏行业协会、通威集团、协鑫科技、大全能源、新特能 源、亚洲硅业 ...

格隆汇1月8日丨盟科药业(688373.SH)公布，近日，上海盟科药业股份有限公司收到国家知识产权局下 发的《药品专利权期限补偿审批决定》。专利号：ZL200880020610.0，专利名称：用于治疗细菌感染的 抗菌邻-氟苯基噁唑烷酮。 按照中国专利法及其实施细则相关规定，决定给予该专利药品专利权期限补偿，补偿天数1826天，原专 利权期满终止日2028年8月6日，现专利权期满终止日2033年8月6日。药品专利权期限补偿期间，其保护 范围限于国务院药品监督管理部门批准上市的新药，且限于该新药经批准的适应症相关技术方案。 康替唑胺片作为公司核心产品，其药品专利权期限补偿获得审批同意，专利保护期延长至2033年，为公 司核心产品再提供5年的市场保护，将显著提升该药品在国内市场的独占销售窗口期，提升公司的核心 竞争力。 ...

按照中国专利法及其实施细则相关规定，决定给予该专利药品专利权期限补偿，补偿天数1826天，原专 利权期满终止日2028年8月6日，现专利权期满终止日2033年8月6日。药品专利权期限补偿期间，其保护 范围限于国务院药品监督管理部门批准上市的新药，且限于该新药经批准的适应症相关技术方案。 康替唑胺片作为公司核心产品，其药品专利权期限补偿获得审批同意，专利保护期延长至2033年，为公 司核心产品再提供5年的市场保护，将显著提升该药品在国内市场的独占销售窗口期，提升公司的核心 竞争力。 格隆汇1月8日丨盟科药业(688373.SH)公布，近日，上海盟科药业股份有限公司收到国家知识产权局下 发的《药品专利权期限补偿审批决定》。专利号：ZL200880020610.0，专利名称：用于治疗细菌感染的 抗菌邻-氟苯基噁唑烷酮。 ...

来源：新浪财经-鹰眼工作室 资料显示，上海盟科药业股份有限公司位于中国(上海)自由贸易试验区爱迪生路53号1幢1-4层101,2幢， 成立日期2012年8月7日，上市日期2022年8月5日，公司主营业务涉及一家以治疗感染性疾病为核心,拥 有全球自主知识产权和国际竞争力的创新药企业,致力于发现、开发和商业化针对未满足临床需求的创 新药物。主营业务收入构成为：康替唑胺片100.00%。 数据显示，MicuRx (HK) Limited最初持股7075.61万股，占总股本的10.79%。MicuRx (HK) Limited从 2025年9月5日起，第一次减持盟科药业股份，迄今为止，累计减持公司股票73.56万股，累计套现约 596.55万元。 减持期间减持均价（元/股）减持股数（万股）套现金额（万元）减持后持股比例20250905- 202512048.1173.56596.5510.68%合计-73.56596.55- 最新1条卖出记录： 1月6日，盟科药业公告，股东MicuRx (HK) Limited计划在2026年1月28日至2026年4月27日期间，通过 大宗交易或竞价交易方式减持不超过1966.82万 ...

Core Viewpoint - The capital operation of Mengke Pharmaceutical, known as the "first stock of antibiotics," has ended with the termination of its planned private placement of 1.033 billion yuan due to strong opposition from its major shareholder Genie Pharma, leading to significant internal conflicts within the company [1][2][8]. Group 1: Termination of Private Placement - Mengke Pharmaceutical announced the termination of its private placement plan after significant disagreements with its major shareholder Genie Pharma, which opposed the execution of the plan [1][8]. - The company cited that continuing with the stock issuance could negatively impact its stable operational development [1][8]. - Following the termination, Mengke Pharmaceutical plans to explore various financing channels, including engaging new strategic investors and issuing shares to unspecified parties [1]. Group 2: Financial Performance and Background - Mengke Pharmaceutical has been facing financial difficulties, with net losses of 220 million yuan, 421 million yuan, and 441 million yuan from 2022 to 2024, and a net loss of approximately 194 million yuan in the first three quarters of this year [2][3]. - As of June 30, the company had cash and cash equivalents of only 237 million yuan, prompting a shift in the use of IPO funds to supplement working capital [3]. Group 3: Shareholder Dynamics - Genie Pharma, the largest shareholder, has been vocal in its opposition to the private placement, raising concerns about the potential loss of the company's independence and the financial implications of the deal [6][7]. - The proposed private placement would have allowed Haiqing Pharmaceutical to become the controlling shareholder, which raised alarms for Genie Pharma regarding control over the board and company operations [7][8]. - The internal conflict escalated to a point where Genie Pharma sought to replace existing board members, indicating a struggle for control within the company [7].

Core Viewpoint - The capital operation of Mengke Pharmaceutical, known as the "first stock of antibiotics," has been terminated after nearly two months of intense negotiations and opposition from major shareholders, particularly Genie Pharma, regarding a proposed private placement of 1.033 billion yuan [1][2][8]. Group 1: Termination of Capital Operation - On November 17, Mengke Pharmaceutical announced the termination of its plan to issue shares to specific investors due to ongoing opposition from its major shareholder Genie Pharma, which created significant disagreements with other shareholders and management [1][8]. - The company stated that continuing with the stock issuance could negatively impact its stable operational development [1][8]. Group 2: Financial Performance and Background - Mengke Pharmaceutical has faced financial difficulties, reporting net losses of 220 million yuan, 421 million yuan, and 441 million yuan from 2022 to 2024, with a net loss of approximately 194 million yuan in the first three quarters of this year [2][3]. - As of June 30, the company had only 237 million yuan in cash and cash equivalents, prompting a change in the use of IPO funds to supplement working capital [3]. Group 3: Strategic Importance of the Proposed Investment - The proposed investment from Nanjing Haiqing Pharmaceutical was seen as strategically significant for Mengke Pharmaceutical, as it could enhance production and research capabilities, reduce costs, and support project commercialization with approximately 1 billion yuan in funding [3][4]. Group 4: Shareholder Disputes - The major shareholder Genie Pharma opposed the private placement, citing concerns over the uncertainty of Haiqing Pharmaceutical's involvement, potential impacts on the company's independence, and the lack of direct operational experience in the infection treatment field [6][7]. - Genie Pharma's opposition escalated to a direct power struggle over the control of the board, with proposals to remove existing directors and replace them with individuals closely associated with Genie Pharma [7][8].

Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the supplementary application of the drug "Kangti Zuoan Tablets" and the clinical trial of "MRX-5 Tablets," indicating significant progress in the company's product pipeline and supply chain management [1][4]. Group 1: Kangti Zuoan Tablets - The drug "Kangti Zuoan Tablets" is a new generation oxazolidinone antibiotic developed by the company, approved for treating complex skin and soft tissue infections, and was launched in China in June 2021 [2]. - The recent approval allows Jiangsu Xuantai Pharmaceutical Co., Ltd. to be added as a contracted manufacturing enterprise, and Chongqing Boteng Pharmaceutical Technology Co., Ltd. will supply the active pharmaceutical ingredient [1][3]. - This development is crucial for ensuring stable product supply and meeting market demand, although sales are subject to policy and market environment influences [3]. Group 2: MRX-5 Tablets - "MRX-5 Tablets" is a new type of benzoborazole antibiotic intended for treating infections caused by non-tuberculous mycobacteria (NTM), with an increasing incidence and prevalence of NTM infections [5][6]. - The company has received approval to conduct further clinical trials for a new 200mg specification of MRX-5, which has shown good antibacterial activity and safety in previous trials [4][6]. - MRX-5 has completed Phase I clinical trials in Australia and has been granted orphan drug designation by the US FDA, indicating its potential in the market [6][7].

Group 1 - Company received approval from the National Medical Products Administration for the supplementary application of the drug "Kangti Zuoan Tablets" and the supplementary application for clinical trials of "MRX-5 Tablets" [1] - "Kangti Zuoan Tablets" is a new generation oxazolidinone antibiotic designed for treating complex skin and soft tissue infections, approved for marketing in China since June 2021 [1] - The approval allows Jiangsu Xuantai Pharmaceutical Co., Ltd. to act as a contract manufacturer, utilizing raw materials from Chongqing Boten Pharmaceutical Technology Co., Ltd., enhancing the product supply chain and ensuring stable supply [1] Group 2 - "MRX-5 Tablets" is a novel benzothiazole antibiotic aimed at treating infections caused by non-tuberculous mycobacteria (NTM), with increasing incidence and prevalence of NTM diseases [1] - The drug shows good antibacterial activity against common NTM, with favorable safety and pharmacokinetic properties demonstrated in animal and human trials [1] - The company has completed Phase I clinical trials in Australia, achieving expected goals, and received orphan drug designation from the US FDA for "MRX-5" [1][2] - The approval of a new 200mg specification for clinical trials will facilitate further clinical research [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug "Kangti Zuoan Tablets," marketed as "Youxitai," allowing Jiangsu Xuantai Pharmaceutical Co., Ltd. to act as a contract manufacturer [1] Group 1 - The approval includes the use of raw materials from Chongqing Boten Pharmaceutical Technology Co., Ltd. for the commercial production of Kangti Zuoan Tablets [1] - The company has also initiated additional clinical trials for the MRX-5 Tablets in a new 200mg specification, targeting infections caused by non-tuberculous mycobacteria sensitive to this product [1]